Drug Profile
Cancer vaccine - Bioimmulance
Alternative Names: MAGE-A4/Survivin cancer vaccine; Survivin/MAGE-A4 cancer vaccineLatest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Bioimmulance
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(Second-line therapy or greater, Treatment-experienced) in Japan (Intratumoural, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(Second-line therapy or greater, Treatment-experienced) in Japan (SC, Injection)
- 07 Sep 2011 Phase-I clinical trials in Cancer in Japan (Intratumoural)